HomeCompareCARA vs ADC

CARA vs ADC: Dividend Comparison 2026

CARA yields 37.59% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CARA wins by $24.3K in total portfolio value
10 years
CARA
CARA
● Live price
37.59%
Share price
$5.32
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$203.2K
Annual income
$32,602.95
Full CARA calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — CARA vs ADC

📍 CARA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCARAADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CARA + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CARA pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CARA
Annual income on $10K today (after 15% tax)
$3,195.49/yr
After 10yr DRIP, annual income (after tax)
$27,712.51/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, ADC beats the other by $40,965.19/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CARA + ADC for your $10,000?

CARA: 50%ADC: 50%
100% ADC50/50100% CARA
Portfolio after 10yr
$191.1K
Annual income
$56,700.12/yr
Blended yield
29.67%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

CARA
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$14.50
+172.6% upside vs current
Range: $1.00 — $30.00
Altman Z
-4.0
Piotroski
1/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CARA buys
0
ADC buys
0
No recent congressional trades found for CARA or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCARAADC
Forward yield37.59%4.13%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$203.2K$178.9K
Annual income after 10y$32,602.95$80,797.29
Total dividends collected$150.0K$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$14.50$81.06

Year-by-year: CARA vs ADC ($10,000, DRIP)

YearCARA PortfolioCARA Income/yrADC PortfolioADC Income/yrGap
1← crossover$14,459$3,759.40$10,990$580.36+$3.5KCARA
2$20,552$5,080.25$12,301$860.26+$8.3KCARA
3$28,739$6,748.40$14,104$1,298.62+$14.6KCARA
4$39,570$8,819.34$16,691$2,008.16+$22.9KCARA
5$53,689$11,348.75$20,580$3,205.09+$33.1KCARA
6$71,837$14,390.67$26,754$5,330.02+$45.1KCARA
7$94,862$17,995.60$37,196$9,345.14+$57.7KCARA
8$123,711$22,208.66$56,244$17,523.09+$67.5KCARA
9$159,438$27,067.93$94,286$35,736.21+$65.2KCARA
10$203,202$32,602.95$178,949$80,797.29+$24.3KCARA

CARA vs ADC: Complete Analysis 2026

CARAStock

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Full CARA Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this CARA vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CARA vs SCHDCARA vs JEPICARA vs OCARA vs KOCARA vs MAINCARA vs NNNCARA vs EPRTCARA vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.